Optiver Holding
SYRE icon

Optiver Holding’s Spyre Therapeutics SYRE Stock Holding History

Optiver Holding’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5K Buy
288
+48
+20% +$1.81K ﹤0.01% 1151
2025
Q4 		$7.86K Sell
240
-260
-52% -$6.79K ﹤0.01% 1200
2025
Q3 		$8.38K Buy
+500
New +$8.15K ﹤0.01% 1406

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Optiver Holding's SYRE Position: Q1 2026 in Review

Optiver Holding increased its Spyre Therapeutics (SYRE) stake by 20% in Q1 2026, buying an estimated $1.81K and bringing the position to 288 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

Optiver Holding first reported a position in SYRE in Q3 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Optiver Holding held 288 shares of Spyre Therapeutics worth $14.5K as of Q1 2026.
  • Optiver Holding bought 48 Spyre Therapeutics shares in Q1 2026, an estimated $1.81K.
  • Spyre Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1151 holding.
  • Optiver Holding first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.